Scarica l'app Stockscreener
107.88
0.88%
-0.585
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Japan Approves Incyte Lymphoma Therapy, Expanding DLBCL Options - MyChesCo
Incyte stock: Is INCY outperforming the healthcare sector? - MSN
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
INCY Reiterates by HC Wainwright & Co. -- Price Target Maintained at $140 - GuruFocus
H.C. Wainwright reiterates Incyte stock rating on Medicaid settlement - Investing.com
H.C. Wainwright reiterates Incyte stock rating on Medicaid settlement By Investing.com - Investing.com Canada
Key deals this week: GSK, Incyte, Ingredion, OpenAI, and more - MSN
Incyte nears $2B deal for blood disorder drug developer Star Therapeutics: FT - MSN
Truist raises Incyte stock price target to $105 on VWD outlook - Investing.com UK
Incyte reports tafasitamab combo benefit in Phase III FrontMIND study - MSN
Incyte Corporation’s Stock Price Soars to $103.66, Marking a Robust 5.54% Uptick - Smartkarma
Why is Incyte stock gaining today? - Investing.com
Incyte Corporation (INCY) Reaches Settlement with CMS Over Medic - GuruFocus
INCY Upgraded by BMO Capital -- Price Target Raised to $94.00 - GuruFocus
Incyte settles Medicaid rebate litigation with CMS, expects $246 million benefit - Investing.com
Incyte settles CMS lawsuit over Opzelura Medicaid rebate rules - StreetInsider
Incyte reaches CMS settlement, to record $246M non-cash benefit after Opzelura ruling - TradingView
BMO upgrades Incyte stock rating on strategic progress By Investing.com - Investing.com South Africa
Incyte Stock: Is INCY Outperforming the Healthcare Sector? - Yahoo Finance
Incyte (INCY) Secures Approval for Minjuvi in Japan - GuruFocus
Incyte Trial Data Support New First-Line Approach in Lymphoma - MyChesCo
Incyte StockStifel lifts price target after bile duct disease data - AD HOC NEWS
Incyte secures Japanese approval for lymphoma drug Minjuvi - grafa.com
Incyte Corp (INCY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Japan clears Incyte’s Minjuvi for relapsed DLBCL patients - Stock Titan
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - Yahoo Finance Singapore
INCY News | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte Corp. stock underperforms Monday when compared to competitors - MSN
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised) - Yahoo Finance
Incyte Corp (INCY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Incyte Corp (INCY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Incyte Corp (INCY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Incyte Corp (INCY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Incyte Corp (INCY) Institutional Confidence - TradingKey
Incyte Corp (INCY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Incyte Corp (INCY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Incyte Corp (INCY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Incyte's Vega deal adds VGA039 with $1 billion sales potential by 2034 - S&P Global
Incyte to buy Vega Therapeutics in hematology deal worth up to $2B - MSN
Analysts Conflicted on These Healthcare Names: Incyte (INCY), Intellia Therapeutics (NTLA) and Halozyme (HALO) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Pfizer (PFE) and MBX Biosciences, Inc. (MBX) - The Globe and Mail
Incyte slides as investors digest updated INCA033989 (mutCALR) data and a cautious analyst take - Quiver Quantitative
BMO reiterates Incyte stock Underperform on ET/MF trial data - Investing.com UK
BMO reiterates Incyte stock Underperform on ET/MF trial data By Investing.com - Investing.com Nigeria
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review - Yahoo Finance
Stifel reiterates Incyte stock rating on drug trial data review - Investing.com
Stifel reiterates Incyte stock rating on drug trial data review By Investing.com - Investing.com Canada
0.03%
1.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):